Under Therapeutic Pressure: ELCC Session Highlights How Tumor Switching is Reshaping the Treatment Landscape

… to develop complex resistance. Under therapeutic pressure, tumor evolution—or “switching”—can manifest in various ways, … transformation data and complex interpretation. “ctDNA is helpful if we witness systemic progression, …

Using Early ctDNA, Study Findings Inform Prognostic Model

… PhD, at the 2025 World Conference on Lung Cancer, evaluated circulating tumor DNA (ctDNA) as a predictive biomarker for consolidation …

The Promise of Artificial Intelligence-Aided Pathology in Thoracic Oncology

Toward Durable Disease Control in EGFR-Mutant (mt) NSCLC: Interpreting the Survival Signals from FLAURA2 and MARIPOSA

… shifted from identifying the correct target to preventing tumor evolution beyond it. Two phase III trials—FLAURA2 and … with liver metastases, TP53 co-mutations, and detectable circulating tumor DNA (ctDNA). Toxicity differed from chemotherapy-based …

Gender Disparity in Lung Cancer

… 2 Jyoti Patel, MD For example, germline mutations in tumor suppressor genes such as TP53, DNA repair pathway genes such as BRCA1, BRCA2, and … these emerging survival patterns, including differences in tumor biology discussed above as well as treatment response …

Mounting Evidence Supporting Neoadjuvant ChemoIO Means Surgeons Must Adapt

Circulating Tumor Cell–Derived Patient eXplants: A New Tool for SCLC Research

… Circulating Tumor Cell–Derived Patient eXplants: A New Tool for SCLC …

Debaters Argue Merits of Surgery in Malignant Meso in Light of MARS2 Data

… of surgery in the treatment of malignant mesothelioma began circulating. And after a debate at the 2024 Targeted … mesothelioma is maximal cytoreduction to remove all visible tumor, but an R0 resection is not possible. Surgery alone is …

Phase II Trial Evaluates Amivantamab Plus Lazertinib in EGFR-Mutant Lung Cancers With New or Progressing Brain Metastases or Leptomeningeal Disease

… the formal response criteria. However, when we examined CSF circulating tumor cells (CTCs), 67% of patients demonstrated a reduction in tumor burden. This discordance suggests that conventional …